Effect of phencyclidine derivatives on anxiety-like behavior using an elevated-plus maze test in mice

Advances in Clinical and Experimental Medicine

Volumn 21, Issue 3, 2012, Pages 307-312

  Hajikhani, Ramin ^a   Ahmadi, Abbas ^a   Naderi, Nima ^b   Yaghoobi, Kayvan ^b   Shirazizand, Zahra ^b   Rezaee, Nazereh M ^a   Niknafs, Babak N ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anxiety like behavior; Elevated plus maze test; Mice; Phencyclidine derivatives

Indexed keywords

ANXIOLYTIC AGENT; HYDROXYL GROUP; PHENCYCLIDINE; PHENCYCLIDINE B; PHENCYCLIDINE DERIVATIVE; PHENCYCLIDINE F; PHENCYCLIDINE L; PHENCYCLIDINE M; PHENCYCLIDINE P; PHENCYCLIDINE S; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; ELECTRON; HYDROPHILICITY; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN;

ANIMALIA; MUS;

EID: 84863752307     PISSN: 18995276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Diagnostic and Statistical Manual of Mental Disorders Washington D.C.: American Psychiatric Association, 4, 2000.
2. Lakhan SH E, Vieira KF: Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr J 2010, 9, 42, 1-14.
3. Kemp JA, Foster AC, Wong EHF: Non-competitive antagonists of excitatory amino acid receptors. Trends Neurosci 1987, 10, 294-298. (Pubitemid 17090076)
4. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA: NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991, 254(5037), 1515-1518. (Pubitemid 21917493)
5. Ahmadi A, Khalili M, Hajikhani R, Naserbakht M: New morpholine analogues of phencyclidine: Chemical synthesis and pain perception in rats. Pharmacol Biochem Behav 2011, 98, 227-233.
6. Mori A, Noda Y, Mamiya T, Miamoto Y, Nakajima A, Furukawa H, Nabeshima T: Phencyclidine-induced discriminative stimulus is mediated via Phencyclidine binding sites on the N-methyl-D-asparate receptor-ion channel complex, not via sigma receptors. Behav Brain Res 2001, 119, 33-40. (Pubitemid 32063352)
7. Geller EB, Adler LH, Wojno C, Adler MW: The Anticonvulsant Effect of Phencyclidine in Rats. Psychopharmacology 1981, 74, 97-98. (Pubitemid 11126468)
8. Balster RL, Chait LD: The behavioral pharmacology of Phencyclidine. Clin Toxicol 1976, 9, 513-528.
9. Hajkhani R, Solati J, Ahmadi A, Salari AA: The Effect of Phencyclidine New Derivatives on Anxiety Behaviors in Rats. Iran J Basic Med Sci 2010, 13 (2), 16-23.
10. Woolverton WL, Balster RL: Tolerance to the behavioral effects of phencyclidine: the importance of behavioral and pharmacological variables. Psychopharmacology 1979, 64, 19-24. (Pubitemid 9227039)
11. Lal H, Emmett-Oglesby MW: Behavioral analogues of anxiety animal models. Neuropharmacology 1983, 22, 1423-1441. (Pubitemid 14175491)
12. Griez EJL: Anxiety Disorders: An Introduction to Clinical Management and Research. John Wiley and Sons 2001.
13. Ninan PT: The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry 1999, 60 Suppl 22, 12-17.
14. Maddox VH, Godefroi EF, Parcell RF: The synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem 1965, 8, 230-235.
15. Ahmadi A, Solati J, Hajikhani R, Onagh M, Javadi M: Synthesis and analgesic effects of 1-[1-(2-methylphenyl)(cyclohexyl)]-3-piperidinol as a new derivative of phencyclidine in mice. Arzneim-Forsch/Drug Res 2010, 60, 492-496.
16. Ahmadi A, Khalili M, Hajikhani R, Naserbakht M: Synthesis and determination of acute and chronic pain activities of 1-[1-(4-methylphenyl) (cyclohexyl)] morpholine as a new phencyclidine derivative in rats. Arzneim-Forsch/Drug Res 2011, 61, 1-11.
17. Ahmadi A, Khalili M, Hajikhani R, Barghi L, Mihandoust F: Synthesis and Determination of Chronic and Acute Thermal and Chemical Pain. Iran J Pharm Res 2010, 9 (4), 379-385.
18. Ahmadi A, Khalili M, Abbassi S, Javadi M, Mahmoudi A, Hajikhani R: Synthesis and determination of acute and chronic pain activities of 1-[1-(4-methylphenyl)(cyclohexyl)] morpholine as a new phencyclidine derivative in rats. Arzneim-Forsch/Drug Res 2009, 59 (4), 202-206.
19. Ahmadi A, Khalili M, Mihandoust F, Barghi L: Synthesis and determination of acute and chronic pain activities of 1-[1-[3-methyphenyl] [tetralyl]] piperidine as a new derivative of phencyclidine via tail immersion and formalin tests. Arzneim-Forsch/Drug Res 2010, 60(1), 30-35.
20. Lister RG: The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berlin) 1987, 92, 180-185.
21. Kinnard WR, Carr CJ: A preliminary procedure for evaluation of central nervous system depressants. J Pharmacol Exp Ther 1957, 121, 354-356.
22. Stephens DN, Meldrum BS, Weidmann R: Does the excitatory amino acid receptor antagonist 2-APH exhibit anxiolytic activity? Psychopharmacology (Berlin) 1986, 90, 166-169. (Pubitemid 16011347)
23. Fryer JD, Lukas RJ: Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999, 288 (1), 88-92. (Pubitemid 29113477)
24. Zarrindast MR, Solati J, Oryan S, Parivar K: Effect of intra-amygdala injection of nicotine and gaba receptor agents on anxiety-like behavior in rats. Pharmacology 2008, 82, 276-284.
25. Adamec R: Transmitter systems involved in neural plasticity underlying increased anxiety and defense-Implications for understanding anxiety following traumatic stress. Neurosci Biobehav Rev 1997, 21, 755-765.
26. Ochoa EL, Li L, McNamee MG: Desensitization of central cholinergic mechanisms and neuroadaptation to nicotine. Mol Neurobiol 1990, 4, 251-287.
27. Olney J, Newcomer J: NMDA receptor hypofunction model of schizophrenia. J Psychiatry Res 1999, 33, 523-533.
28. Martin P, Carlsson M: Systemic PCP treatment elevates brain extracellular 5-H-T: a microdialysis study in awake rats. Neuroreport 1998, 9, 2985.
29. Graeff F, Guimarães F: Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996, 54, 129-142.